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1. Introduction 
1.1 Drug discovery and clinical evaluation 
The discovery of a drug is focused on the goal of producing a useful therapeutic agent 
through a process utilizing the multiple skills and expertise of basic scientists, 
pharmaceutical chemists, toxicologists, clinical investigators, governmental regulators and 
clinicians (Mager DE, 2009; Michel MC, 2009; Nagase H, 2011). Drug development and its 
clinical evaluation is thus a very lengthy and expensive endeavor. One has to first come up 
with a novel mechanism, identifying relevant target(s) and pathway(s) towards formulation 
of a new chemical entity (NCE) to treat a disease. Both in vitro and in vivo models that are 
relevant to the disease form the basis of preclinical testing and identification of lead 
compounds, and the development of an Investigational New Drug (IND), and ultimately the 
entry of only a select few into human clinical trials. Therefore, initial studies in drug 
developments involve the synthesis and extraction of new compounds, their biological 
screening and pharmacological testing, followed by small animal model testing of 
toxicology and safety profiles. These early pharmacokinetic (PK) measurements guide 
researchers to formulate effective pharmaceutical dosage, in vivo stability, elimination and 
eventually the therapeutic index of lead compound(s). In pre-clinical studies, a favorable PK 
outcome can lead to the FDA approval for the phase-I, -II and -III clinical evaluation process 
(Fasolo A, 2009). However, even after clinical approval, drugs have to be continuously 
monitored towards improvements in their bioavailability, therapeutic, and toxicologic 
differences especially in a large patient population with patient-specific variability. For 
example, the azathioprine and mercaptopurine intolerance in patients were found to be 
linked to the deficiency of a metabolic enzyme, thiopurine S-methyltransferase, and formed 
the genetic basis for a molecular diagnostic test to designate specific population (Yates CR, 
et al. 1997). Thus, before testing in humans can start, a significant body of pre-clinical data 
on PK must be compiled and an appropriate dose should be established to ensure human 
safety. Toxicology, pharmacology and pharmaceutical sciences all represent the core of pre-
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clinical drug development which is repeatedly addressed in the clinical trials and post-
clinical approval phases. Each phase of drug development has to be designed to accrue the 
necessary information to assess the probability of success of an NCE which remains the 
fundamental pathway to successful clinical approval (DiazGranados N, 2008). The 
continually expanding knowledge base on the development of new agents and novel 
delivery and formulation strategies are enabling a favorable in vivo PK and a more 
efficacious drug discovery process. Advances in the understanding of multiple factors that 
regulate drug disposition and response in individuals are elucidating the molecular basis of 
ethnic and inter-individual variability in drug action (Xie HG, et al. 2001; Soldin OP, et al. 
2009). Furthermore, due to their in vivo safety and efficacy profiles, a number of natural 
products have recently entered clinical trials as potent anti-inflammatory agents (Basnet P, 
2011; Abdel-Tawab M, 2011), however, their role in drug-drug interaction issues is not being 
addressed in specific patient populations. 
1.2 Importance of preclinical in vivo models 
The use of in vivo models to obtain vast quantities of PK/PD data is a well-established pre-
clinical approach. Before any clinical testing can be initiated in humans, it is important to 
compare the PK and PD properties of candidate molecules; model potential relationships 
among dose, concentration, efficacy, and/or toxicity in appropriate animal model systems 
(Sausville EA, 2006; Kennedy AJ, 2010; Miyagawa F, 2010). For a more thorough and 
comprehensive understanding of the experimental approaches in mouse models, please refer 
to ‘The handbook of experimental animals’ by Elsevier Academic Press (Hans H, 2004). 
Numerous inbred mouse models are available to delineate the efficacy of drugs in specific 
disease models, such as the WKY and SHR strains which are optimal for studying 
antihypertensive and antidiabetic agents (Kennedy AJ, 2010) and the leptin knockout mice 
(ob/ob) as models for obesity and insulin resistance (Lijnen HR. 2011). Several disease specific 
knockout and transgenic mouse models are also used, for instance, to study cardiovascular 
drugs (Avila MD, 2011; Xiangdong L, 2011; Zaragoza C, 2011) and autoimmune disease 
targeting agents (Gulinello M, 2011; Schroeder MA, 2011). Immunodeficient animals, such as 
nude, SCID and SCID/NOD tumor xenograft mouse models, are also important for testing 
and development of new chemotherapeutic drugs (Sausville EA, 2006; Khan N, 2009; Umar A, 
2010; Baiocchi M, 2010). The utility of these animal models to study cancer-initiating cells 
which are responsible for tumor recurrence and resistance, is showing great promise towards 
development of more potent anti-cancer agents (Wee B, 2011).  
Studies completed in laboratory animals give useful indications for drug development, and 
many lead compounds that show compromised potency in vitro can turn out to be more 
effective in vivo because of their favorable pharmacokinetics, e.g. greater absorption, better 
distribution and stability, etc. Studies are first initiated in small animal models, e.g. mouse, 
rats, rabbits, to test for acute, sub-chronic and then chronic toxicity. In acute toxicity tests, 
one administration of the drug or chemical is given to each animal in order to generate a 
safe and effective dose–response curve. Appropriate pharmacological testing in disease 
models are carried out to determine 50% effective dose (ED50). For some anti-tumor and 
anti-viral agents, even IC90 (90% inhibitory concentration) is incorporated in these initial 
studies in order to demonstrate the potency (Cummins CL, et al, 2003). Following acute 
administration, analytical methods are developed for determination of absorption, 
distribution, metabolism and excretion (ADME) of the drug. The subchronic toxicity tests 
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usually involve animals exposed to the drug for 60–90 days duration. Both multiple 
administrations and/or continuous exposure via food or water to one dose level of a 
chemical per animal, is carried out to measure drug accumulation and possible toxicities. 
Depending on the animal species being used, the chronic toxicity tests usually takes 2 to 5 
years to complete and may include both multiple administrations per day or continuous 
exposure measures via subcutaneous or intramuscular depot. Indeed, alterations in drug 
elimination rates and toxic outcomes are particularly important when drugs are given 
repeatedly. Certain therapeutic agents tend to accumulate toxic concentrations in tissues 
and organs when eliminated slowly or their metabolism is compromised, drug 
accumulation may occur with toxic concentrations reached in important tissues and organs. 
Alternately, faster elimination than expected due to increased breakdown of the agent may 
cause sub therapeutic concentrations to be reached, thus enabling the rapid selection of drug 
resistance, often observed with antibiotics and antimicrobials. Therefore, a commonly 
employed formula for ascertaining therapeutic dose levels in both pre-clinical and clinical 
models is, “Maintenance dose = Dosing amount X Dosing interval”. Both in vitro and in vivo 
uptake experiments in rats have been able to predict the hepatic and renal clearance of a 
number of drugs, and were able to delineate drugs which are substrates for drug-
metabolizing enzymes and drug-transporters (Watanabe T, et al. 2009). Several transgenic 
and knockout mouse models have also been used to understand the role of drug-
metabolizing enzymes and drug-transporters, and in the discovery of novel inhibitors of 
these factors in order to increase drug efficacy in vivo (Salphati L. et al., 1998; Shitara Y. et al., 
2002; van Waterschoot RA, 2011). Because the drug levels in plasma or tissues are often 
more predictive of a safe dose which can be extrapolated to humans, preclinical toxicology 
in animals underscores the importance of PK studies. The choice of endpoints and correct 
surrogate markers are very important and careful consideration must be given to the 
definition of therapeutic efficacy. Safety is the most important concern in clinical trials and 
then the emphasis is directed towards drug efficacy. In addition to examining safety and 
effectiveness, studies in animal models also emphasize critical aspects of drug kinetics, 
including proper dose determination, biotransformation, drug binding to plasma proteins, 
induction or inhibition of enzymes and potential interaction with other drugs (Evans W, et 
al. 1989; Evans W, et al. 1992). The choice of representative controls is also an essential 
component in PK studies in both preclinical and clinical settings. Indeed, most concurrently 
controlled trials are double-blind and randomized studies where both objective evidence 
and subjective complaints are taken into account towards a clearer representation of 
therapeutic value of the drugs being tested for a specific disease indication.  
2. Pharmacokinetics 
Cell membranes are biologic barriers that selectively inhibit passage of drug molecules. Drugs 
may cross cell membranes by passive diffusion, facilitated passive diffusion, active transport, or 
pinocytosis. Thus, drug PK is critically affected by body mass, obesity as well as age and health 
status of the subject. Since numerous currently used drugs may manifest toxic effects and may 
have long-term teratogenic effects, therapeutic drug monitoring in children has become an 
essential component of clinical testing as emphasized by pediatric pharmacokinetics (McLeod 
HL, et al. 1992). In general, drug elimination may occur through biotransformation and by the 
passage of molecules from the blood to the outside of the body through urines, bile or other 
routes. Therefore, the PK study relies on measurements of levels of the test drug in blood and 
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urine at various times after administration. If a drug is ineffective at the given dose, the above 
measurements resolve issues of efficacy vs. poor absorption or rapid elimination. All the organs 
except the lungs are in parallel because they are perfused by a fraction of the whole blood in 
each passage. Drug levels in blood achieve equilibrium with drug entry into subvascular tissues 
and drug levels which are excreted or metabolized. PK studies investigate the parameters 
which regulate therapeutic concentrations of drugs and/or its metabolites, and their movement 
in different parts of the body (Ritschel WA & Kearns GL. 1999). Initial studies of in vivo PK 
measurements required complex mathematical modeling of absorption (A) and distribution 
(D). Absorption indicates the passage of drug molecules from the administration site to the 
blood, and distribution indicates the passage of drug molecules from blood to the tissues. As the 
roles of liver and kidney in drug disposition become clearer, essential components, such as the 
rate of drug metabolism (M) and drug excretion (E) from the body are increasingly examined. 
The choice of best route of drug administration establishes the best dose regimen and 
determines whether dose individualization would be necessary based on patient and disease 
characteristics, e.g. drug elimination rates (Ritschel WA & Kearns GL. 1999). Recent findings 
clearly indicate that these two later parameters in ADME are also critically regulated by 
intracellular drug metabolizing enzymes and membrane bound drug-transporters (Wikinski, S. 
2005). Flexibility in the design of studies is very desirable at this stage. Furthermore, extremely 
slow metabolism of certain drugs may result in their accumulation and toxicity, thus mandating 
changes in subsequent doses. All drugs are eventually excreted from the body, and many 
require bio-activation to form the active compound [Figure-1]. 
 
Fig. 1. Drug absorption and disposition. A graphic representation of drug disposition is shown 
where drug entry first occurs in the blood circulation and then drugs pass through tissues 
and organs. Blocks designate the equilibrium seen between drug absorption, distribution, 
metabolism and elimination (ADME) parameters.  
2.1 Routes of administration 
To gain a proper understanding of drug PK, first of all, it is essential to understand, compare 
and contrast different routes of drug administration, and acknowledge their advantages and 
disadvantages. Drug absorption is determined by the drug's physicochemical properties, 
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formulation and route of administration. Depending on the preclinical findings on ADME in 
animal models, administration could be either Enteral (oral, buccal/sublingual) or Parenteral 
[subcutaneous (SC), intramuscular (IM) or intravenous (IV)] (Evans W, et al. 1992; Ritschel 
WA. 1999; Hans H. 2004). Dosage forms (e.g., tablets, capsules, solutions) are formulated to be 
given by various routes. Regardless of the route of administration, drugs must be in solution to 
be absorbed. Unless given IV, a drug must cross several semipermeable cell membranes before 
it reaches the systemic circulation. Oral drug delivery is highly advantageous since it is 
convenient and cheap and patient compliance is good. Different formulations such as fast 
release tablets, capsules, enteric coated pills, suspensions and mixtures can be used to enhance 
drug uptake by intestinal epithelial lining and to facilitate drug stability in the stomach and 
small intestine. However, there are several disadvantages related to oral delivery, especially its 
inefficiency in reaching therapeutic plasma levels. Low oral bioavailability can be due to 
decreased stability and solubility of the drug in the gastrointestinal (GI) tract. In addition, the 
GI lining expresses a number of Cytochrome P450 (CYP450) enzymes and drug-efflux 
transporters which can suppress drug uptake and enhance metabolism.  
Presystemic metabolism is a significant challenge even after intestinal uptake due to the 
transport of drugs to the liver via the hepatic portal vein. Examples of drugs that experience 
a significant ‘first-pass effect’ are imipramine, morphine, propranolol, buprenorphine, 
diazepam, midazolam, demerol, cimetidine, and lidocaine. The first pass effect and liver 
metabolism can be bypassed via buccal or sublingual administration which significantly 
increases bioavailability (Brockmeier D. 1988; Haber PS, 1996; Brown AS, 1998). In recent 
years, the first pass effect has also been exploited in converting an inactive form of a drug 
(e.g. 3-methylmorphine or Codeine) to the pharmacologically active form (morphine) by 
first pass metabolism (KuKanich B. 2010; Nieminen TH, 2010). However, under most 
circumstances, the oral drug delivery approach is inconvenient and only small doses can be 
accommodated. Hence, several strategies to directly infuse drugs, so that rapid plasma 
levels can be achieved, are SC, IM and IV delivery methods. One advantage of SC delivery is 
that drugs can be self-administered. Although absorption is slow via this route, it can be 
improved by local massage or heat. Unfortunately, this method can be painful and irritant 
drugs can cause local tissue damage. In contrast, IM injections can accomodate a larger 
volume of drug delivery, and now a number of drugs are using IM strategies to facilitate 
depot formation for sustained release effects. The trained personnel are required for IM 
injections, however, the site of injection can significantly influence systemic absorption of 
the drug. A quicker response is possible with IV drug delivery and large doses may be given 
into a peripheral vein over 1 to 2 minutes or longer by infusion. In most of the pre-clinical 
PK studies, this is the route of choice for drug infusion and monitoring of toxicity, especially 
of chemotherapeutic agents (Wong J, 2008; Serwer LP, 2011). The IV method however 
requires trained personnel to maintain sterility, and pyrogen testing, while the cost of 
preparation, transport and storage of such preparations can be expensive. 
2.2 Fick's law of diffusion 
Drugs diffuse across a cell membrane from a region of high concentration to one of low 
concentration. Diffusion rate is directly proportional to the gradient but also depends on the 
molecule's lipid solubility, size, degree of ionization, and the area of absorptive surface. Lipid-
soluble drugs diffuse most rapidly and small molecules tend to penetrate membranes more 
rapidly than larger ones. Drug effectiveness using any of the above delivery approaches 
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ultimately requires transport across membrane barriers. In addition, membrane transporters 
play active roles in both drug influx and efflux and therapeutic levels in sequestered tissues. 
Oral drugs need efficient transport across intestinal epithelial lining and subsequently through 
the endothelial lining of blood capillaries. Drugs diffuse across a membrane in an attempt to 
equalize the drug concentration on both sides of the membrane. Fick's law was the driving 
force that represented a tendency for molecules to move from levels of higher concentration to 
lower concentration in accordance with random molecular motion. This has been attributed to 
the fact that the rate of diffusion across a membrane is directly proportional to the 
concentration gradient of a substance on either side of the membrane and is inversely related 
to the thickness of the membrane. Therefore, the rate of drug transport across the membrane 
has been described by the Fick's law of diffusion [Figure-2]. 
 
Fig. 2. Fick's law of diffusion. Molecules tend to move from a higher concentration to a lower 
concentration where the rate of diffusion across a membrane is directly proportional to the 
concentration gradient and inversely related to the thickness of the membrane. Rate of 
movement of Molecules per unit time = (Area)x(Permeability coefficient)x(Ch - Cl)/ Thickness.  
Previously, most drugs were thought to cross biologic membranes by passive diffusion 
which occurs when the drug concentration on one side of the membrane is higher than on 
the other side. Therefore, in the past, the absorption principles for a drug molecule were 
primarily dependent on its aqueous diffusion, especially within large aqueous components 
(e.g. interstitial space, intracellular cytosol). This view of drug movement is dictated by their 
ability to transport drugs across epithelial and endothelial membrane tight junctions 
(Matsuhisa K, 2009; Furuse M. 2010). Both physiological conditions and disease status, 
especially inflammatory cytokines, are known to regulate drug transport from the blood to 
the tissues via these tight junctions (Tarbell JM. 2010; Srinivas SP. 2011). This drug 
absorption into tissues is also facilitated via transport through aqueous pores which allows 
diffusion of molecules with molecular weights up to 30 kDa. Lipid diffusibility of drugs is 
also an essential component in a drug’s ability to be transported from one compartment to 
another since many lipid barriers separate tissue compartments and drug partition 
coefficients between aqueous and lipid environments. In addition, the ionization states of 
drugs have been studied to determine their PK efficacy and bioavailability. However, rapid 
dissolution and absorption is not always the objective. Sometimes a slower release is 
required, e.g. for Tolbutamide (used to lower blood sugar): a more sustained release is 
better, causing a more gradual reduction in blood sugar (Tassaneeyakul W, 1992; Lee CR, 
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2003). In addition, as mentioned earlier, the rate at which a drug dissolves is also dependent 
on its solubility and acid-base dissociation constants, according to the ‘Henderson 
Hasselbalch equation, e.g. free acid or base forms of Penicillin achieve different serum 
levels. Also, absorption of antimicrobials can be extended by using IM injection of their less 
insoluble salt forms (e.g. Penicillin G). For other drugs, suspensions or solutions in 
nonaqueous vehicles (e.g., crystalline suspensions for insulin) are designed to delay 
absorption. Most drugs are weak organic acids or bases, existing in un-ionized and ionized 
forms in an aqueous environment. The un-ionized form is usually lipid soluble (lipophilic) 
and diffuses readily across cell membranes. The ionized form has low lipid solubility 
(hydrophilic) and high electrical resistance and thus cannot penetrate cell membranes easily. 
The proportion of the un-ionized form present (and thus the drug's ability to cross a 
membrane) is determined by the pH and the drug's pKa (acid dissociation constant). 
However, whether a drug is acidic or basic, most absorption occurs in the small intestine 
because the surface area is larger and membranes are more permeable.  
Although the surface area of the epithelial lining allows for high rate of absorption, the 
endothelial lining of blood vessels is relatively non-porous. For numerous diseases of the 
central nervous system (CNS), e.g. gliomas, AIDS dementia, epilepsy, etc., drug absorption 
into the brain has been a significant problem (Aragon-Ching JB, 2007; Reichel A. 2009). This 
is especially due to the presence of blood-brain barrier (BBB) and blood-cerebrospinal fluid 
(CSF) barrier (Mehdipour AR, 2009; Johanson CE, 2011). The membranes between the blood 
and brain have effectively no pores and prevent many polar materials (often toxic materials) 
from entering the brain. However, smaller lipid materials or lipid soluble materials, such as 
diethyl ether, halothane, can easily enter the brain. Several in vitro models have been 
developed to overcome drug inefficacies in the brain (Wilhelm I, 2011; Tóth A, 2011; 
Potschka H. 2010). The absorption of a drug and/or its metabolites into the kidney is also 
very crucial in dictating drug elimination and in suppressing accumulation of toxic levels of 
the drug. This is especially important since the membranes of the renal tubules and renal 
glomerulus are quite porous allowing non-polar and polar molecules (~ M.W. 70 kDa) to 
pass through and allows for rapid excretion of polar substances (drug and waste 
compounds) (Verbeeck RK, 2009; Hartmann B, 2010).  However, lipophilic compounds or 
non-ionized species are reabsorbed dependent on the pH and pKa of the drug which 
dictates the elimination rate and is measured in patients via creatinine clearance rates (CCR) 
(Kooman JP. 2009; Bogard KN, 2011; Fesler P, 2011), a parameter which will be emphasized 
later in this chapter in relation to drug-transporter expression in the liver and the kidney.  
In contrast to passive diffusion, active transport is selective, requires energy expenditure and 
may involve transport against a concentration gradient. Active transport seems to be limited to 
drugs structurally similar to endogenous substances (e.g. ions, vitamins, sugars, amino acids). 
These drugs are usually absorbed from specific sites in the small intestine. As will be discussed 
in more detail in this chapter, we have discovered that complex mathematical modeling is 
necessary to determine the volume of distribution and therapeutic window for drug action. 
Furthermore, we now appreciate the role of special carriers present on lipid membranes that 
regulate drug transport into various compartments. 
2.3 Compartmental models and important PK parameters 
Compartmental analysis uses kinetic models to describe and predict the concentration-time 
curve. PK compartmental models are often similar to kinetic models used in other scientific 
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disciplines such as chemical kinetics and thermodynamics. At different times after drug 
administration, much information can be obtained on the passage of drug molecules 
between blood and tissues and on the rate of drug elimination in the urine or feces by 
measuring the concentrations of drugs in different body fluids or within tissues [Figure-3]. 
The advantage of compartmental over some non-compartmental analyses is the ability to 
predict the concentration at any time post drug infusion; however, the disadvantage of this 
complex system is the difficulty in developing the proper model and validating the proper 
rate constants for the ADME principles.  
 
Fig. 3. Compartment models used in drug disposition measurements. The simplest PK compartmental 
model (Model-I) is the one-compartmental PK model with IV bolus administration and first-
order elimination. In multicompartmental modeling, the rate constants for drug transport to-and-
from the central reservoir (blood) to tissues such as fat, bone or skin (k12 and k21) and the rate of 
elimination by the kidney and liver (kel), are needed to be determined.  
The planning, execution and analysis of the results of a PK study depends closely on the 
purpose of the experiment. For example some studies may be planned to get accurate 
estimates of drug absorption or to obtain information on the drug elimination kinetics 
(Evans W, et al. 1989; Evans W, et al. 1992; Ritschel WA & Kearns GL. 1999). Consequently 
the experimental protocols may vary considerably. Hence, to effectively plan a 
pharmacokinetic experiment, the following conditions should be well defined: the route of 
drug administration, dose regimen, which tissues to sample, sample times, analytical 
method, and the animal species. In clinical settings, the inclusion and exclusion criteria of 
subjects for observation and the population kinetics of the drug are taken into account.  
Mathematical models are essential tools in PK measurements because these models aid in 
defining a set of parameters that describe drug disposition and the relationship of underlying 
biological processes. In model building, the linear compartmental models, the clearance 
models, and the multiexponential functions, constitute various passages of drugs through 
different compartments. Starting from a simple description of the drug profile in the plasma, 
the experimenter may gain better insight and reasonable approximations of the biological and 
physiological aspect of the system. The analysis of the assumptions, approximations of the 
model, and a comparison of the performance of different models may thus be very useful in 
identifying new aspects of the system and to design experiments able to deliver continuous 
and increasingly relevant knowledge. This chapter will only touch briefly on each of these 
important PK parameters to familiarize the reader with the concepts, but for detailed 
descriptions of these mathematical models the reader is requested to consult the following 
more comprehensive reviews on PK (Evans W, et al. 1992; Ritschel WA & Kearns GL. 1999).  
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During mathematical calculations estimate drug disposition rates, to compartmental models 
have been beneficial tools to understand the effects of the overall system under study. Both 
single and multicompartmental modeling is needed to obtain accurate measures of drug 
levels in tissues and possible efficacies at site of action. This is carried out following oral or 
IV infusion of the drug and sampling of plasma concentrations at different time points. The 
following parameters are determined simultaneously which include peak plasma 
concentrations (Cmax), peak time to attain Cmax (Tmax), half-life (t1/2), and area under the 
plasma concentration curve (AUC). It should be noted that each parameter of this model 
which deals with the rate constants, do not represent a single physical variable, but a set of 
variables which may not be distinguished at a given time point. The kinetic profile of a 
single drug in the plasma may be well summarized by the above parameters, and is 
depicted in the plasma concentration vs. time curves [Figure-4]. 
 
Fig. 4. The plasma concentration vs. time curve. The curve on the left illustrates plasma 
concentration of the drug at different times following IV introduction. The onset of drug 
effect, magnitude and duration of drug effect, as well as the therapeutic window for the 
drug can be determined from these in vivo measurements. The line graph on the right 
illustrates the rate of change in plasma concentration (∆C/∆t) of the drug which is 
dependent on the initial drug concentrations. This type of rate change analysis is helpful in 
determining the rates of elimination and metabolism, as well as the half-life of the drug. 
The Cmax and Tmax may be directly obtained from experimental observations of each subject 
and these two parameters are closely dependent on the experimental protocol because the 
concentrations are always decreasing after the initial dose. The peak time corresponds to the 
time of infusion if the drug is infused by IV at a constant rate. However, after oral 
administration Cmax and Tmax are dependent on the extent and the rate of drug absorption, 
and on the disposition profile of the drug. Consequently these two parameters can 
characterize the properties of different formulations of the drug in the same subject. All of 
the initial information on Cmax and Tmax should be generated when presenting the design of 
a pharmacokinetic study.  
The half life of a drug has a significant relevance in the determination of dosage of a drug. 
Half-life (t1/2) is derived from a mathematical property of the monoexponential function curve 
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which results in elimination of half of the drug after a fixed time interval [Figure-5]. This 
means that the kinetic profile of many drugs is well approximated by a monoexponential 
function in the terminal phase and consequently it makes sense to define the half-life, or 
terminal half-life, in order to characterize the slope of the curve in this phase. Therefore, the 
drug elimination rate (Kel) is the sum of the rate constants due to the rate of metabolism (Km) 
and the rate of excretion (Kex), and it can be defined as Kel = Km + Kex. Since drug elimination 
is an exponential process, the time required for a twofold decrease is proportional to ln(2) or 
0.693 which equals the natural logarithm of two, and t1/2 = (0.693)/Kel. Therefore, if Co is the 
drug concentration at time 0 and λ is dependent on the half-life of the curve, then the following 
relationship can be extrapolated as: t1/2 = 0.693 /λ. With a single compartmental model, a 
monoexponential function can thus be used to calculate plasma concentration at a specific time 
after administration. This can be written as:- c(t) = C0 x e–λ.t where c(t) is the drug concentration 
at time t. Indeed, the terminal half-life is often used to describe decay of the drug concentration 
during the terminal phase.  
 
Fig. 5. The half life of drugs in vivo. Half life of a drug is dependent on Rate of Elimination of 
the drug. The semi-log plot shows plasma levels of drugs (Cp) and different time post 
infusion (e.g. t1, t2, etc.). It is a constant rate of decline which is independent of the starting 
time of drug administration. 
 
Fig. 6. The AUC analysis. The AUC is calculated by adding the different AUC-segments 
together. Each very narrow segment has an area of Cp.dt. The AUC depends on the volume 
of distribution (V) and the rate of elimination (Kel). It is calculated from time 0 
(administration time, Cp0) to infinity as shown in equations 1 and 2. 
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The extent and rate of drug absorption and distribution thus play important roles in 
pharmacokinetics. These parameters are usually referred to as the drug bioavailability (BA). 
The area under the plasma concentration curve (AUC) value is very useful for calculating the 
relative efficiency and BA of different drugs and possibly their metabolic products, e.g. the 
metabolic products of the anti-cancer agent irinotecan (Mathijssen RH, et al. 2001).  The AUC is 
calculated by adding the AUC-segments together under the plasma concentration vs. time 
curve. Each very narrow segment of the cure has an area equal to plasma concentration at 
different time intervals (i.e. Cp x dt) [Figure-6]. The AUC is calculated from time 0 
(administration time) to infinity after single drug administration, and within the dose interval 
after multiple dose treatment. By integrating this equation that t1/2 = 0.693 / λ between 0 and 
infinity, we can obtain the values for AUC = Co/λ.  This suggests that the area under the curve 
can also be computed easily from the Co, e and λ values. The Co and λ can be estimated by a 
non-linear regression technique or by linearizing the data using the log-transformation.  
The AUC can also be used to measure both the volume of distribution (Vd) and the drug 
elimination process. Under very general assumptions, the AUC is closely dependent on the 
drug amount that enters into the systemic circulation and on the ability that the system has 
to eliminate the drug (clearance). Therefore, AUC can be used to measure the drug amount 
absorbed or the efficiency of physiological processes that characterize drug elimination. 
Clearance (CL), on the other hand, depends on the functionality of the eliminating organs, 
i.e. the kidney or the liver, therefore possible inefficiencies of these organs can have 
consequences on clearance, AUC and drug levels. For example, a fraction of a dose may be 
metabolized during the early passage through the gastrointestinal (GI) tract or through the 
liver after an oral dose and part of the dose may not even reach the blood due to drug 
malabsorption. The consequences are incomplete absorption of the drug into the systemic 
circulation and incomplete drug availability which may result in an ineffective treatment. 
Evidence that drug PK may drastically be changed due to either IV or oral administration of 
the anti-diabetic agent metformin, were also clearly shown in these early studies 
(Pentikainen PJ, 1979). From the plasma AUC and the CL, it is possible to compute the drug 
amount which enters into the systemic circulation in a particular subject. The following very 
general definitions can be given: CL = D/AUC x Vd where CL = drug amount eliminated 
per unit of time/drug concentration in plasma, and the volume of distribution (Vd) = drug 
amount in the body/drug concentration in plasma [Figure-7].  
For drugs with narrow therapeutic index and significant side-effect profiles, it is common 
that multiple exponential terms are needed to fit the plasma concentrations after an IV 
bolus, and more complex mathematical modeling is carried out to more accurately 
determine the PK parameters. In order to get a good interpolation of the data after oral or 
extravascular administration, multiple exponential terms should be added to the above 
simple equations of PK. Although plasma drug concentrations are increasing just after oral 
administration and decreasing after the peak time, the predicted data may be biased when 
fitted by a monoexponential function, and interpolation of oral or IV profile may be 
obtained by adding new exponential terms with the following equation: C(t) = A1 x e–λ1.t + A2 
x e–λ2.t, which is called a biexponential function. In order to get the best fit of the 
experimental data and the best accuracy in the estimated parameters, a number of these 
exponential terms should be chosen. By taking into account the numerous compartments 
that the drug can be distributed to, as well as the number of rate constants necessary to 
ultimately determine the drug concentration remaining at a certain time, the above equation 
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is frequently changed to represent an integration function: C(t) = ΣAi x e–λi.t. Following these 
calculations, the initial drug level and the AUC can be computed by the integrated 
parameters of the curve as represented by the equation: Co = Σ Ai x e x AUC = Σi Ai /λi 
where Co is equal to 0 after oral or extravascular administration. This literally means that 
the terminal half-life is always represented by 0.693/λn, where the λn is the lowest exponent.  
 
Fig. 7. Multicompartmental Models. Frequently, a multicompartmental model and equation 
are implemented where the rate constants for drug absorption and distribution are 
calculated. In this model, the k0 represents initial absorption process and the processes of 
tissue absorption, distribution and excretion are denoted by using multiple rate constants 
such as k12, k21, and k10. In this multicompartmental system, a drug appears to be dissolved 
in total body volume which is also referred to as the 'apparent' volume of distribution (VD). 
The VD can be used to determine how readily a drug will displace into the body tissue 
compartments relative to the blood, where: VP = plasma volume; VT = apparent tissue 
volume; fu = fraction unbound in plasma and fuT = fraction unbound in tissue.  
Although these multiexponential functions require complex calculations, they are needed to 
determine drug disposition in both preclinical and clinical settings. The importance of such 
rigorous calculations was recently underscored by findings that Clopidogrel, an anti-platelet 
drug used to treat heart attack and stroke, which had a very narrow therapeutic index and 
caused significant side effects in the elderly (Roden, DM. & Stein, CM. 2009), needed careful 
dose adjustments depending on the patient’s renal clearance rates (Goteti K, 2008).  
The majority of drugs currently used have approximately a biexponential profile in plasma after 
an intravenous bolus, but there are exceptions especially after oral administration. Indeed, very 
often the drug profile is not monoexponential, and the concentrations of many drugs in plasma 
and tissues may not decay in a linear fashion (Evan W., 1989). Highly comprehensive data on 
drug profiles, not only in the plasma, but also in all other tissues or fluids, and especially 
addressing the differences due to the routes of administration are needed. Therefore, for a given 
drug, a single kinetic profile may be well summarized by Cmax, Tmax, t1/2 and AUC, however, 
with drugs having more than one profile, the mean and standard deviation of these individual 
parameters, may be needed to summarize the drug kinetics especially in multiple animals or in 
the whole population (Dreisbach AW, 2008 & 2009).  
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3. Drug metabolizing enzymes and drug-transporters 
Until recently, when a drug exhibited poor oral bioavailability, it was generally assumed 
that this was due to either physicochemical problems associated with poor solubility in the 
GI fluids or inability to diffuse through the intestinal membrane, or alternatively, due to 
significant first-pass hepatic metabolism. Based on a series of cellular, animal and human 
studies, we now realize that both intestinal metabolic enzymes and efflux transporters, 
working together as a protective mechanism, may be responsible for the poor bioavailability 
of a number of drugs (Furuta T, 1998; Schellens JH, 2000; Luo FR, 2002). Drug metabolizing 
enzymes and drug-transporters critically regulate the extent of drug distribution throughout 
the body and the rate of drug clearance from the body (Volm M, 1991; Wacher VJ, 1995). The 
CYP450 enzymes are the major enzymes involved in drug metabolism and bio-activation, 
accounting for ∼75% of the total metabolism. The CYP enzymes catalyze the oxidation of 
organic substances such as lipids, steroidal hormones, and xenobiotics, and they are the 
primary enzymes involved in drug metabolism and bioactivation (Guengerich, 2008). The 
first evidence of the Cyp450 system in regulating drug-interactions was observed when the 
effects of ketoconazole, a potent inhibitor of multiple drug-metabolizing enzymes, were 
shown to increase digoxin absorption and disposition in a rat model (Salphati, L. 1998). The 
ATP-binding cassette (ABC) transporters are a family of transmembrane proteins that 
harness the energy of adenosine triphosphate (ATP) hydrolysis to translocate a variety of 
substrates including lipids, sterols, metabolic products and drugs across extra- and 
intracellular membranes (Davidson et al., 2008).  
 
 
Table 1. Both drug metabolizing enzymes and drug-transporters regulate ADME. 
Over the past several decades, considerable efforts to delineate the characteristics 
influencing activation and regulation of these enzymes and proteins have provided a 
valuable foundation of data illustrating their different effects on the distribution, 
metabolism and clearance of drugs. Increasing evidence suggests that CYP450 enzymes and 
ABC transporters significantly impact drug bioavailability, and a variety of factors including 
age, sex, health and genetics influence their activity (Sai K, 2003; Allabi AC, 2004). The 
following section summarizes how the aforementioned factors may impact PK and PD to 
ultimately guide health care providers in making informed decisions about the type of drug, 
dosage and dosage scheduling for safe administration. Since all drugs are eventually 
excreted from the body, and many require bio-activation to form the active compound, the 
field of PK has begun to focus not only on drug metabolism by the CYPs, but also on the full 
spectrum of drug disposition, including a growing list of transporters that influence 
absorption, distribution and excretion [Table-1]. 
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3.1 The CYP450 system 
CYP450 enzymes are present in most tissues of the body and play important roles in 
hormone synthesis and breakdown (including estrogen and testosterone synthesis and 
metabolism), cholesterol synthesis and vitamin D metabolism (Salphati, L. 1998; 
Guengerich, 2008; Bjorkman S. 2005). CYP450 enzymes also function to metabolize 
potentially toxic compounds, including drugs and products of endogenous metabolism such 
as bilirubin, principally in the liver. A subset of CYP450 enzymes play important roles in the 
synthesis of steroid hormones (steroidogenesis) by the adrenals, gonads, and peripheral 
tissue: CYP11A1 (steroid 20ǂ-hydroxylase), CYP11B1, CYP17A1, CYP21A1 (in the adrenal 
cortex conducts 21-hydroxylase activity) and CYP19A all catalyze aromatization of 
androgens to estrogens. These enzymes belong to the superfamily of proteins containing a 
heme cofactor and, therefore, are hemoproteins which have been named on the basis of their 
cellular (cyto) location and spectrophotometric characteristics (chrome). When the reduced 
heme iron forms an adduct with carbon monoxide (CO), the P450 enzymes absorb light at 
wavelengths near 450 nm, identifiable as a characteristic Soret peak, thus the name CYP450.  
These drug metabolizing enzymes are primarily membrane-associated proteins, located 
either in the inner membrane of mitochondria or in the endoplasmic reticulum of cells. 
Often, they form part of multi-component electron transfer chains, called P450-containing 
systems. Each enzyme is termed an isoform since each derives from a different gene. It 
should be noted, however, that structural similarity of enzymes cannot be used to predict 
which isoforms will be responsible for a drug's metabolism. Because of the vast variety of 
reactions catalyzed by CYPs, the activities and properties of the many isoenzymes differ in 
many respects. Each CYP450 enzyme and their isozymes can metabolize multiple drugs and 
recognize molecules with disparate structures as their substrates. Drug interactions 
involving the CYP450 isoforms generally result from one of two processes, enzyme 
inhibition or enzyme induction. Enzyme inhibition usually involves competition with 
another drug for the enzyme binding site. This process usually begins with the first dose of 
the inhibitor and onset and offset of inhibition correlate with the half-lives of the drugs 
involved (Dossing M, 1983; Murray M, 1990). Enzyme induction occurs when a drug 
stimulates the synthesis of more enzyme protein, enhancing the enzyme's metabolizing 
capacity. It is somewhat difficult to predict the time course of enzyme induction because 
several factors, including drug half-lives and enzyme turnover, determine the time course of 
induction. Broadly, the CYPs are divided into two categories, i.e. Phase-I enzymes that 
introduce or remove functional groups in a substrate through oxidation, reduction or 
hydrolysis; and Phase-II enzymes that transfer moieties from a cofactor to a substrate via 
conjugation. According to a standardized nomenclature system adapted in 1996, the CYPs 
are divided into 18 families and 43 subfamilies on the basis of amino acid sequence 
homology (Ingelman-Sundberg M. 2004 & 2009; Nelson, DR. 2009). A schematic of recent 
guidelines for the nomenclature of CYP450 isoenzyme families, is provided [Figure-8].  
The Phase-I CYP450 is a gene superfamily consisting of more than 57 genes coding for 
functional proteins, and 58 pseudogenes. The most common reaction catalyzed by the Phase-I 
enzymes is a monooxygenase reaction, e.g. insertion of one atom of oxygen into an organic 
substrate (RH) while the other oxygen atom is reduced to water: RH + O2 + 2H+ + 2e– → ROH 
+ H2O. The majority of these genes are polymorphic. Current information on genetic variants 
can be found at the human CYP allele home page (http://www.imm.ki.se/CYPalleles/ and 
http://www.cypalleles.ki.se/). More than 434 different alleles of the genes encoding 
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xenobiotic metabolizing P450 enzymes are presented on this site. Among these, three 
subfamilies of CYPs, including CYP1, CYP2, and CYP3, contribute to the oxidative metabolism 
of more than 90% of clinically used drugs. Overall, approximately 10 of the CYP450 enzymes 
are responsible for the metabolism of a large number of pharmacologic agents in human 
beings, and six of them are considered most important: CYP3A4, CYP2D6, CYP2C19, CYP2C9, 
CYP1A2 and CYP2E1. CYP3A4 is the most abundantly expressed cytochrome and composes 
30 to 40% of the CYP in the liver and in the small intestine. CYP2D6 is implied (at 20%) in the 
metabolism of active compounds and CYP2C9 coupled with CYP2C19 can metabolize at least 
15% of commonly prescribed drugs (Desta Z, 2006).  
 
Fig. 8. CYP450 gene nomenclature. Enzymes that share at least 40% sequence homology are 
assigned to a family designated by an Arabic numeral, whereas those sharing at least 55% 
homology makeup a particular subfamily designated by a letter (A, B, C, etc.). Single 
members of a subfamily represent a particular enzyme and are designated by the number 
following the subfamily description (e.g. CYP2D6, CYP3A4). For each enzyme, the most 
common or “wild-type” allele is denoted as -1, and allelic variants are sequentially 
numbered as they are identified (i.e. -2, -3, etc.). 
The most clinically important Phase-II enzymes are uridine diphosphate 
glucuronosyltransferase (UGT), sulfotransferase (SULT), glutathione S-transferases (GST), 
N-acetyltransferase (NAT) and thiopurine methyltransferase (TPMT). The human UGT 
superfamily is a group of conjugating enzymes that catalyze the transfer of the glucuronic 
acid group of uridine diphosphoglucuronic acid to the functional group (e.g. hydroxyl, 
carboxyl, amino, and sulfur) of a specific substrate. Glucuronidation increases the polarity of 
the substrates and facilitates their excretion in bile or urine. Seventeen human UGT genes 
have been identified thus far and are classified into two subfamilies (i.e. UGT1 and UGT2) 
(Nagar S, 2006). The super family of human GST catalyzes the conjugation of glutathione 
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(GSH) to a wide range of endogenous metabolites and xenobiotics including alkylating and 
free radical generating anticancer drugs (Townsend DM, 2005; Board PG. 2007). NAT2 plays 
an important role in the activation and/or deactivation of a large and diverse number of 
aromatic amine and hydrazine drugs used in the clinic, and therefore the NAT2 genotype is 
particularly relevant to the response to these drugs (Hein DW. 2002). TPMT is best known 
for its key role in the metabolism of the thiopurine drugs (e.g., 6-mercaptopurine, 
azathiopurine and 6-thioguanine) which are clinically used to treat cancers or as immuno-
suppressants (Booth RA, 2011). 
3.2 The ABC and SLC transporters 
Our knowledge of membrane expressed drug transporters has increased considerably in 
the past decade. Several transporters have been cloned and advances have been made in 
understanding their structure- function and characteristics (Davidson AL, 2008; Borst P, 
2000; Shitara Y, 2002 ). Many tissues express these drug transporters such as the brain, 
liver, kidney and intestine; and they play an important role in defining characteristics of 
drug absorption, distribution and excretion of drugs. Thus, they are pivotal in affecting 
absorption and tissue distribution, hepatic uptake and export, as well as renal and biliary 
elimination of a variety of drugs. Conversely, the active transporters dictate the entry of 
drugs into different compartments and actively efflux drugs from intracellular 
compartments. Thus, drug transport via these membrane pumps could be classified as 
passive or active [Figure-9].  
 
Fig. 9. Simple diffusion vs. active and passive transporters. Simple diffusion of drug across 
cellular membranes occur via the ‘Fick’s law’. However, transporters on cell membranes can 
both facilitate and inhibit drug transport. 
URL: http://year12biologyatsmc.wikispaces.com/Active+Transport) 
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A drug that moves across a membrane along its concentration gradient without expending 
metabolic energy is said to be transported passively. The intestinal uptake of glucose in the 
human body serves as a good example of passive transport (Awad WA, 2007; Durán JM, 
2004). Passive transport can be divided into two sub-types. The first two involves 
spontaneous movement of membrane permeable substances across the membrane utilizing 
the laws of simple diffusion. The second type of non-energy dependent transport is 
facilitated diffusion where the movement of membrane impermeable substances across the 
membrane is aided via transporters and via co-transport of other charged ions (Dobson PD, 
2008; Visentin M, 2011).  Both passive and carrier-mediated drug transport processes are 
known to coexist in tissues and regulate drug concentrations within subvascular sites 
(Sugano K, 2010; Lau YY, 2007; Varghese Gupta S, 2011). 
Conversely, active transport requires energy and may involve transporting the drug against 
their concentration gradient, involving multiple saturable carriers (Choo EF, 2000; Hinoshita E, 
2000; Conrad S, 2002; Krishnamurthy P, 2006). The primary active transporters utilize 
adenosine triphosphate (ATP) to produce energy for transport. The transport protein itself 
consists of an ATPase, which hydrolyzes ATP for the required energy. However, a secondary 
active transport mechanism also exists where the transporter protein does not have a direct 
ATP coupling and utilizes the potential gradient created when ions are transported across the 
membrane by primary active transport, but these are mostly found in bacteria or protozoans 
(Boiangiu CD, 2005; Simon J, 2008). Although, a few of these active ion-pumps have been of 
potential importance in cancer therapeutics, e.g. proton pump inhibitors (Harguindey S, 2009). 
In general, drug transporters that are of clinical significance have been divided into two main 
classes; the solute carrier family (SLC) of passive transporters and the ATP binding cassette 
(ABC) family of active transporters [Table-2 & Table-3].  
3.2.1 The ABC transporters 
The drug-efflux function of ABC transporters enables extrusion of a wide range of 
substrates from the inside to the outside of a cell membrane or organelle (Jones PM, 2009; 
Locher KP. 2009; Degorter MK, 2011). They are known to transport lipids and sterols, ions 
and small molecules, drugs and large polypeptides. P-gp (ABCB1) is ubiquitously expressed 
in a number of important organs such as liver, intestine, lymphocytes, placenta and the 
brain endothelial cells. P-gp can transport mainly cationic or electrically neutral substrates 
as well as a broad spectrum of amphiphilic substrates. The ABCC family members confer 
MDR to organic anion compounds, and MRP1 is more ubiquitous than MRP-2. 
Interestingly, their expression can either be at the apical (AP) or on the basolateral (BL) 
membranes of epithelial or endothelial barriers. The ABCG2 transporter, also known as 
BCRP (breast cancer resistance protein) are also expressed on apical surfaces and confer 
resistance to Topoisomerase inhibitors and doxorubicin [Table-2]. 
The best characterized ABC-transporter is P-glycoprotein (also known as P-gp, MDR-1 or 
ABCB1) (Brinkmann U, 2001; Fromm MF. 2003; Kroetz DL, 2003). MDR-1 displays a broad 
substrate spectrum comprising of both neutral and cationic organic compounds. Another 
ABC-transporter, recently cloned from a drug resistant breast cancer line, is BCRP (a.k.a. 
ABCG2) and substrate specificities and tissue localization of BCRP have been found to be 
similar to that of MDR-1 (Jonker JW, 2000; Krishnamurthy P, 2006). BCRP is also referred to 
as a half transporter since it has one transmembrane domain and functions as a dimer to 
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transport a variety of drugs. The immunosuppressant cyclosporine-A and verapamil, a 
calcium channel antagonist, are competitive inhibitors of MDR-1 mediated efflux (also 
referred to as MDR-modulators) and have often been used in the laboratory to determine 
MDR-1 specific drug-efflux (Eilers M, 2008; Roy U, 2009). A newly discovered group of ABC 
transporters is the MDR associated proteins (MRPs) also referred to as the ABCC family of 
transporters (Gradhand U, 2008). MRPs are found to cotransport drugs along with 
glutathione (GSH) or transport GSH-drug conjugates and glucuronide-drug conjugates. 
Amongst the nine members of the MRP transporters family, the first five (MRP-1, MRP-2, 
MRP-3, MRP-4 and MRP-5) are frequently associated with the efflux of therapeutic agents. 
MRP-1, MRP-2 and MRP-3 transport hydrophilic anionic compounds, large molecules and 
peptidomimetics; however, both MRP-4 and MRP-5 transport small polar compounds such 
as nucleosides, cyclic nucleotides and nucleoside analogs (Schuetz JD, 1999). The 
overexpression of ABC transporters had been shown to result in chemotherapeutics being 
pumped out of cells faster than they can enter, and is an well accepted mechanism leading 
to the development of multidrug resistance (MDR) in cancer cells (Gottesman MM, 2002; 
Luqmani YA. 2005; Tiwari AK, 2011). Recent studies by us, and others, have also shown that 
several anti-HIV-1 drugs, especially HIV protease inhibitors (HPIs) and nucleoside analog 
reverse transcriptase inhibitors (NRTIs) are substrates of ABC-transporters (Choo EF, 2000; 
Roy U, 2009) and their expression on both lymphocytes and BBB endothelial cells (ECs) can 
suppress drug entry into the cellular and anatomical reservoirs of HIV-1 (Eilers M, 2008; 
Tarbell JM. 2010; Shen S, 2010). The polarized expression of MRPs regulates the directional 
transport of drugs in and out of various tissue compartments. Both P-gp and MRP1 are 
predominantly expressed in the human lung; thus, these transporters may be pivotal in the 
protection against toxic compounds.  
 
Table 2. ABC family of drug transporters. The gene name and common protein names for the 
most common transporters are shown. Their tissue distribution, expression polarity (apical 
or basal) and representative drugs that are transported by each of the drug-efflux pumps, 
are shown. (Adapted from Bluth MH, 2011).URL: http://dx.doi.org/10.2147/PGPM.S18861 
3.2.2 The SLC transporters 
The solute carrier family functions by facilitative diffusion and secondary active transport 
(Shitara Y, 2002; Hagenbuch B, 2003; Niemi M, 2004; Lau YY, 2007; Visentin M, 2011). SLC 
transporters, also known as the organic anion transporter polypeptide (OATP) belong to a 
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large superfamily that comprises of approximately 300 SLC genes classified into 43 families. 
The SLC transporters transport both endogenous molecules like amino acids, sugars etc. and 
many exogenous drugs [Table-3]. They are located on the cell membrane as well as on the 
intracellular membrane of organelles. Except for SLC22A11 (OAT4) all others are expressed 
on basolateral membranes. They can transport a variety of small molecules and inhibitors of 
the SLC transporters have proved useful in the treatment of a variety of disorders, 
including depression, epilepsy and Parkinson's disease (Kuroda M, 2005; Gether U, 2006; 
Thwaites DT, 2011). Variance in the expression and function of these transporter proteins 
can significantly impact the PK profile of a number of drugs.  
Uptake transporters belong to the SLC family while efflux transporters belong to the ABC 
family. Many of these drug transporter proteins contain polymorphisms which can 
significantly alter their function. Within the last decade more information has become 
available reinforcing the fact that polymorphisms which effect expression or activity of the 
drug transporters contribute to the variability seen in the drug disposition between 
individuals. A number of studies have demonstrated the importance of P-gp for drug 
disposition in humans (Fromm MF, et al, 2003). Chemotherapeutic drugs (e.g. paclitaxel), 
uricosuric agents (e.g. probenecid), and the leukotrienes (LT) receptor antagonist (e.g. MK-
571), are known inhibitors of MRPs (Eilers M, 2008). A number of preclinical and clinical 
trials are also being carried out to discover new and more effective efflux pump inhibitors 
(EPIs). Initial studies showed that PSC 833, a P-gp specific EPI was able to increase the 
efficacy of vincristine and digoxin in rat models (Song, S. 1999). In recent years, both 
verapamil and cyclosporine-A analogs are showing significant promise as safe and effective 
EPIs (Bauer F, 2010; Kolitz JE, 2010; O'Brien MM, 2010; Patel NR, 2011).  
 
Table 3. SLC family of drug transporters. The gene name and common protein names, tissue 
distribution, polarity (apical or basal) and representative drugs transported by each, are 
shown. (Addapted from Bluth MH, 2011). 
URL: http://dx.doi.org/10.2147/PGPM.S18861 
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4. Pharmacogenomics 
Even using the same medications, different patients respond in different ways. Defining the 
changes seen in drug efficacy and toxicity are of crucial significance since PK measurements 
alone cannot explain such variability (Kuehl P, 2001; Evans WE, 1999; Kroetz DL, 2003; Lai 
Y, 2011).  The intrapatient variability and large population differences suggest that genetic 
inheritance may be a critical determinant of the therapeutic responses to drugs which are 
substrates for ABC-transporters and CYP450 enzymes (Ameyaw MM, 2001; Dorne JL, 2002; 
Evans WE, 2001). Although we know many nongenetic (or epigenetic) factors influence the 
effects of medications, including age, organ function, concomitant therapy, drug interactions 
and the nature of the disease, there are now numerous examples of cases in which inter-
individual differences in drug response are attributed to sequence variants in genes 
encoding drug-metabolizing enzymes and drug transporters. Moreover, recent findings 
demonstrate that genetic differences in both drug metabolizing enzymes and drug 
transporters ultimately regulate the individualistic differences in drug PK (Evans WE, 2003; 
Staatz CE, 2010). Because most drug effects are determined by the interplay of several gene 
products that influence the PK and PD of medications, including inherited differences in 
drug targets (receptors) and drug disposition (metabolizing enzymes and transporters), the 
genetic characteristics in different patient populations, as well as within individuals, have 
become increasingly important in regulating PK. This new field of Medicine is now known 
as pharmacogenomics (PG).  
A gene is considered to be polymorphic when the frequency of a variant allele in a  
specific population is at least 1% (Sachidanandam R, 2001). More than 1.4 million single-
nucleotide polymorphisms (SNPs) were identified in the initial sequencing of the  
human genome, with over 60,000 of them in the coding region of genes 
(www.ncbi.nlm.nih.gov/SNP/GeneGt.cgi?geneID=5243). Some of these SNPs have already 
been associated with substantial changes in the metabolism or effects of medications and 
some are now being used to predict clinical response. The burgeoning field of PG uses these 
genome-wide approaches to elucidate the inherited differences between persons and their 
drug responses (Lamba JK, 2002; MacPhee IA, 2005; Tamura A, 2007a ; Song IS, 2008; Staatz 
CE, 2010a). It has been suggested that 20 to 95 % of the variability in drug disposition and 
effect can be attributed to genetics; therefore, considerable efforts to investigate the genetic 
factors influencing drug response via PG studies hold the promise of personalized medical 
care in the future. Such an approach focuses on drugs and drug combinations that are 
optimized to each individual’s unique genetic makeup (Tamura A, 2007b; Staatz CE, 2010b). 
Mutations play a clear role in the functioning of the majority of the body’s organs (lung, 
liver, brain, etc.) in which CYP and ABC transporter expression may regulate drug 
distribution and clearance. For example, mutations in the ABC transporter, cystic fibrosis 
transmembrane conductance regulator (CFTR) is responsible for the development of the 
lung disorder cystic fibrosis, while the cause of Tangier disease, a high cholesterol-related 
condition, is attributed to mutations in ABCA1 (van der Deen et al., 2005). Other studies 
provide evidence that genetic polymorphisms exert an effect on interethnic variation and 
frequency of CYP and multi-drug resistance gene (MDR1) alleles among Orientals, 
Caucasians and Africans (Iida A, 2002; Lai et al., 2011). Furthermore, interpatient variability 
in drug response and toxicity to standard doses of the most commonly prescribed 
chemotherapeutic agents is often explained, in part, by genetic polymorphisms in genes 
encoding CYP enzymes and ABC transporters. Single nucleotide polymorphisms (SNPs) 
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account for 80% of all sequence variations residing in genes and these sequence variations 
can result in a multitude of adverse drug reactions (Lee et al, 2010). We may be able to 
facilitate personalized clinical treatment of pain and opioid addiction by understanding the 
PK and PD of methadone. Methadone, a P-gp substrate primarily metabolized by CYP3A4 
and CYP2B6, has a narrow therapeutic index and large interpatient variability. Genetic 
polymorphisms in genes coding for the methadone-metabolizing enzymes and P-gp 
contribute to the interindividual variability of methadone kinetics and methadone blood 
concentrations (Li et al., 2008). Ensuing discussion illustrates the relevance of cancer 
pharmacogenomic studies in optimizing chemotherapeutic response by enhancing the 
efficacy and safety of some select chemotherapy drugs. 
4.1 Polymorphisms in the CYP-450 genes 
Polymorphisms within the CYP genes include gene deletions, missense mutations, 
deleterious mutations creating splicing defects or premature stop codon and gene 
duplications, which can result in abolished, reduced, normal or enhanced enzyme activity 
(Ball SE, 1999; Lamba JK, 2002; Daly AK. 2006; Bluth MH, 2011) [Table 4]. A number of 
studies have shown interindividual variability and tissue specificity in the expression of 
cytochrome P450 gene expression (Koch I, et al, 2002). As a result, patients can be classified 
into four phenotypes based on the level of a CYP enzyme activity: poor metabolizer 
(abolished activity), intermediate metabolizer (reduced activity), extensive metabolizer 
(normal activity), and ultrarapid metabolizer (enhanced activity). Substantial evidence 
suggests that genetic polymorphisms within the CYP genes have significant impact on drug 
disposition and/or response. The lack of functional CYP3A5 may not be readily evident, 
because many medications metabolized by CYP3A5 are also metabolized by the universally 
expressed CYP3A4. For medications that are equally metabolized by both enzymes, the net 
rate of metabolism is the sum of that due to CYP3A4 and that due to CYP3A5; the existence 
of this dual pathway partially obscures the clinical effects of genetic polymorphism of 
CYP3A5 but contributes to the large range of total CYP3A activity in humans. Notably, the 
most pharmacologically and clinically relevant CYP polymorphisms are found in CYP2D6, 
CYP2C9, and CYP2C19 genes (Ingelman-Sundburg M. 2004; Bluth MH, 2011). Of the Food 
and Drug Administration (FDA)-approved drug labels referring to human genomic 
biomarkers, 62% pertain to polymorphisms in the CYP enzymes, with CYP2D6 (35%), 
CYP2C19 (17%), and CYP2C9 (7%) being the most common [Table-2]. The genetic basis of 
CYP3A5 deficiency is predominantly a SNP in intron 3 that creates a cryptic splice site 
causing 131 nucleotides of the intronic sequence to be inserted into the RNA, introducing a 
termination codon that prematurely truncates the CYP3A5 protein. Although it is now 
possible to determine which patients express both functional enzymes (i.e., CYP3A4 and 
CYP3A5), the clinical importance of these variants for the many drugs metabolized by 
CYP3A remains unclear. Differences in the CYP450 genotypes may contribute to the inter-
ethnic variations in the disposition and response of substrate drugs (Burk O, 2002; Rettie AE, 
2005; Lim HS, 2007). However, pharmacogenetic testing for drug metabolizing enzymes is 
not yet frequently implemented in the clinic practice (Gardiner SJ, 2005). 
The most common functional polymorphisms occurring in few of the major human CYP 
genes, along with allele frequencies and functional effects, are provided in Table-4. CYP1 
genes are mainly expressed in extrahepatic tissues and have been linked to bioactivation of a 
variety of carcinogens. Multiple SNPs in CYP1 increase their functional activity by inducing 
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gene expression or protein stability and have been linked to ethnic differences in  
PK (Mcilwain CC, 2006). The CYP1A1 polymrphism, CYP1A1*2C is associated with 
increased lung cancer risk in African Americans. Their role in estrogen activation has also 
linked several CYP1A1 genotypes to increased risk of prostate, breast and ovarian cancers.  
 
 
 
 
 
Table 4. (Continued) 
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Table 4. Most common functional polymorphisms in major human CYP genes (adapted 
from Bluth MH, 2011).  
DOI: http://dx.doi.org/10.2147/PGPM.S18861 
Since both CYP1A2 and CYP2A6 can convert nicotine to cotinine, polymorphisms in these 
enzymes are associated with nicotine addiction and tobacco-related cancers. The CYP2B6 
polymorphisms may affect the PK and therapeutic outcome of anti-HIV agents such as 
efavirenz and nevirapine. Indeed, the CYP2B6 variant, Q172H is linked to increased 
breakdown of these anti-HIV drugs in different minority population (Musana AK, 2005). 
The CYP2C9 accounts for ~20% of total hepatic CYP contents, and the CYP2C9*2 (R144C) 
and CYP2C9*3 (I359L) variants may affect PK of numerous important pharmaceutical 
agents such as warfarin, celecoxib, ibuprofen, phenytoin, etc. (Rettie AE, 2005). 
Interestingly, the CYP2C8*3 (R139K; K39R) is associated with lower activity and 
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decreased clearance of both R- and S-ibuprofen, and polymorphisms in CYP2C19 effect 
the response of several classes of drugs, including proton pump inhibitors and 
barbiturates. Although CYP2D6 is involved in the metabolism of ~25% of all drugs, SNPs 
in this gene is mostly due to changes in activity rather than induction in gene expression. 
The CYP2D6 genotypes exhibit large interethnic differences and are of significant 
importance for the dosing of many drugs, including tricyclic antidepressants, 
antiarrhythmics, neuroleptics, analgesics, antiemetics, and anticancer drugs. CYP3A4 has 
the highest abundance in the human liver (~40%) and metabolizes over 50% of all 
currently used drugs. Genetic polymorphisms in CYP3A4 appear to be more prevalent in 
Caucasians, but a direct clinical association has not been established. The clinical 
relevance of CYP3A5 polymorphisms are demonstrated by changes in PK of 
immunosuppressive drugs such as tacrolimus.   
4.2 Polymorphisms in drug-transporters 
Within the SLC superfamily, genetic variance in organic anion-transporting polypeptides 
(OATPs) have been most well characterized (Kameyama Y, 2005; Xu G, 2005; Song IS, 2008; 
Franke RM, 2009). The OATPs are expressed in many tissues like liver, gut and BBB. 
OATP1B1 is one of the major uptake transporters expressed in hepatocytes and transports 
drugs like rifampin and statins etc. This protein is encoded by SLCO1B1, several allelic 
variants of which have been characterized and resulted in decreased transporter activity. 
Another example is OATP-C, which is a liver-specific transporter involved in the 
hepatocellular uptake of a variety of clinically important drugs. A number of functionally 
relevant SNPs have been reported in OATP (Xu G, 2005). In in vitro experiments several 
variants showed reduced uptake of the OATP-C substrates estradiol, estrone sulfate and E2-
17-ǃG (Kameyama Y, 2005). Also, OATP-C variants were found to have reduced cell 
membrane expression compared with the wild-type transporter, especially under 
inflammatory conditions (Le Vee M, 2008). These studies have implicated SLC and OATP 
transporters in drug disposition as well as in normal physiological functions such as 
hormonal signaling.   
Polymorphisms within the ABC transporter super family have been well classified and 
SNPs within ABCB1 or MDR-1 gene (coding for P-gp) serves as an excellent example 
(Hoffmeyer S, 2000; Tanabe M, 2001; Brinkmann U, 2001; Ieiri I, 2004). P-gp genes have a 
wide range of substrates including anti cancer agents, antiarrhythmics and 
immunosuppressive drugs (Drescher S, 2002; Hulot JS, 2005; Elens L, 2007; Thervet E, 2008). 
P-gp expression is widely distributed, liver, the intestines both small and large, and the 
blood brain barrier (BBB) endothelial cells. In addition, polymophisms in both MRP 
(ABCCs) and BCRP (ABCG) are expected to affect the pharmocokintics of several drugs, 
however, a clear pattern of increase or decrease has not yet been decipherable (Tamura A, 
2006a & 2006b). Large inter-individual variability in P-gp expression, almost two to eight 
folds, has been observed in healthy volunteers, leading to significant differences in the 
bioavailability of P-gp substrate drugs within a population. Individual variations in the 
expression of ABC transporters may give rise to a change in the bioavailbility of a particular 
drug and may thus lead to a need for change in dosing. Increasing evidences demonstrate 
that both genotypic and phenotypic polymorphisms may affect membrane transporters and 
that this may well be the cause for variability of a drugs PK profile and toxicity in different 
ethnic groups [Table-5].  
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Table 5. Most common functional polymorphisms in major ABC and SLC transporters 
(adapted from Bluth MH, 2011).  
DOI: http://dx.doi.org/10.2147/PGPM.S18861 
Although our knowledge of polymorphisms in ABC and SLC transporters and their clinical 
association to different drug PK is just developing, the most common functional 
polymorphisms occurring in some of the major transporter genes, along with allele 
frequencies and functional effects, are provided in Table-5. Sequence diversity and 
haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene 
were previously documented (Kroetz DL, 2003; Pauli-Magnus C, 2004; Wang J, 2006; 
Kimchi-Sarfaty C, 2007; Elens L, 2007). Numerous functional implications of these genetic 
polymorphisms in P-gp have also been clearly seen. Several SNPs in the ABCB1 gene, e.g. 
1236C>T and 3435C>T are silent polymorphisms occurring outside of the coding region, 
and do not change the expression of P-gp (Hitzl M, 2001 & 2004). However, these SNPs 
change protein translation and substrate specificities. It has also been shown to affect its 
mRNA, may reduce heteronuclear RNA (hnRNA) processing and translation of the protein. 
Interestingly, these two SNPs have been shown to correlate with ethnic differences in drug 
disposition (Wang D, 2005). The ABCB1*13 genotype has also been shown to affect 
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inhibition by some of the efflux-pump modulators. Several genetic polymorphisms in the 
ABCC1 gene are associated with doxorubicin-induced cardiotoxicity (Wojnowski L, 2005). 
These SNPs were found to be associated with reduced intestinal expression of P-gp, along 
with increased oral bioavailability of digoxin. Several of the ABCC genes, which code for the 
MRP transporters, are known to affect both drug-efflux and apical to basal drug transport 
(Fellay J, 2002). Several ABCC1 SNPs have been associated with anthracycline-induced 
cardiotoxicity. The ABCC2 associated SNPs can alter their expression and localization 
within the cells. Also, several of them, e.g. 3563T>A (V1188E) and 4544G>A (C1515Y), have 
also been associated with anthracycline-induced cardiotoxicity. Several ABCG2 genetic 
variants, which code for the BCRP transporter, are also found to change transporter 
activities and have been associated with MDR tumors. Interestingly, unlike ABCB1 (P-gp), a 
clear clinical correlation with race has not been established with any of these other ABC-
transporters.  
Less emphasis has been placed on changes in passive diffusion due to polymorphisms  
in the SLC genes. Although numerous polymorphisms have been identified and code  
for altered protein such as SLCO1A2, SLCO1B1, CLCO1B3, etc, most of them have  
been shown to suppress facilitated diffusion of their substrates and some of these may 
also affect substrate specificities. However, due to the lack of correlative studies with 
these SNPs occurring in different OATP transporters, we know very little about their 
ultimate effects on drug disposition. Also, less is known about the role of polymorphisms 
in the phase-II enzymes, such as the UGT family members (Guillemette C. 2003; Han JY, 
2006; Lo HW, 2007). Genetic variations in UGT genes alter the function or expression of 
the protein, and potentially modify the glucuronidation capacity of the enzyme. 
Furthermore, SNPs have been identified in most of the human SULT genes (Glatt H, 2004) 
which are associated with altered enzymatic activity and have the potential to influence 
therapeutic response. Two human NAT genes, NAT1 and NAT2, carry functional 
polymorphisms that influence the enzyme activity (Hein DW. 2002; Walker K, 2009) and 
bioactivation (via O-acetylation) of aromatic and hetercyclic amine carcinogens. Patients 
who inherit defective TPMT alleles are at significantly increased risk for thiopurine-
induced toxicity (e.g. myelosuppression) (Peregud-Pogorzelski J, 2010; Ben Salem C, 
2010). Indeed, clinical diagnostic tests are now available for the detection of the SNPs in 
human TPMT gene that lead to decreased or abolished enzyme activity (Nguyen CM, 
2011). 
The above findings reiterate the fact that both genotypic and phenotypic polymorphisms 
may affect variability in drug disposition. Further studies of the polymorphisms in human 
drug-metabolizing enzymes and drug-transporters would shed more light on the subject 
of pharmacogenomics, and could be used in selecting drugs and dosages according to 
genetic and specific individual markers in order to individualize drug therapy. Just as for 
CYP450’s, the possibility of defining patient populations and even individual patients on 
the basis of drug transporter polymorphisms may improve drug safety and efficacy in the 
future. Positron emission tomography (PET) may serve as a very useful tool in 
determining the in vivo effects of transporters and their polymorphisms (Martínez-
Villaseñor D, 2006; Cantore M, 2011). Also in the future it would be valuable to establish a 
correlation between genotype and phenotype and then assess the effects of 
polymorphisms on drug transporter expression and function and in turn, effects on drug 
disposition.  
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5. Pharmacogenomics: A potent tool for maximizing chemotherapeutic response 
5.1 Genetic variations in TMPT may be used to predict toxicity to 6-Mercaptopurine 
Thiopurine methyltransferase (TPMT) catalyzes the S-methylation of 6-MP to form inactive 
metabolites. Genetic variations in the TPMT gene have profound effects on the 
bioavailability and toxicity of 6-MP. It has been demonstrated that about 1 in 300 
individuals inherit TPMT deficiency as an autosomal recessive trait. Patients who carry 
TPMT polymorphisms are at risk for severe hematologic toxicities when treated with 6-MP 
because these polymorphisms lead to a decrease in the rate of 6-MP metabolism (Evans WE, 
1991; Lennard L, 1993). Currently, TPMT testing is being used for dose optimization in 
children with ALL before 6-MP therapy is initiated. 
5.2 Genetic variations in UGT1A1: The basis of inter-patient variability with Irinotecan 
therapy 
Irinotecan (Camptosar®; Pfizer Pharmaceuticals; New York, NY, http://www.pfizer.com) 
has potent antitumor activity against a wide range of tumors, and it is one of the most 
commonly prescribed chemotherapy agents. However, dose-limiting toxicities of irinotecan 
interfere with optimal utilization of this important drug. Once consumed the drug requires 
metabolic activation by carboxylesterase to form the active metabolite 7-ethyl-10-
hydroxycamptothecin (SN-38), which in turn inhibits topoisomerase-I. SN-38 is further 
detoxified via formation of SN-38 glucuronide (SN38G) (Gupta E, 1994). Toxicity of 
irinotecan has been associated with increased levels of SN-38. Clinical pharmacogenetics of 
irinotecan is mainly focused on polymorphisms in UDP-glucuronosyltransferase 1A1 
(UGT1A1), the enzyme responsible for glucuronidation of SN-38 to the less toxic, inactive 
metabolite SN38G (Iyer L, 1998 & 1999). Variations in UGT1A1 activity most commonly 
arise from polymorphisms in the UGT1A1 promoter region that contains several repeating 
TA elements. The presence of seven TA repeats (referred to as UGT1A1*28), instead of the 
wild-type number of six, results in reduced UGT1A1 expression and activity (Beutler E, 
1998). Clinical trials are ongoing to address the impact of dose on irinotecan safety in 
patients with different UGT1A1*28 genotypes (McLeod HL, 2004). 
5.3 CYP2D6 allele activity affects clinical outcome of patients treated with tamoxifen 
One in eight women above seventy develops breast cancer each year in the United States. 
Approximately 70 percent of them have estrogen receptor–positive cancer. Many of these 
women are prescribed tamoxifen following surgical treatment. Tamoxifen is an anti–
estrogen drug that prevents relapse of cancer in 50% of patients and reduces the mortality 
rate by one–third in women with early breast cancer. However, there is a large group of 
women who do not respond to tamoxifen. CYP2D6 encodes for an enzyme involved in the 
metabolism of up to 25 percent of all drugs. The enzyme is present in different forms in 
different people and some lack it entirely. Tamoxifen is a "pro–drug," meaning that it is 
relatively inactive until the liver recruits the CYP2D6 enzyme and converts it into active 
molecules. The key role of CYP2D6 in catalyzing the conversion of tamoxifen to its 
abundant active metabolite endoxifen has been shown to directly affect the clinical outcome 
of patients treated with tamoxifen. This is because the functional alleles of CYP2D6 in some 
individuals result in abolished, decreased, normal, or ultrarapid CYP2D6 enzyme activity. 
Women with nonfunctional and reduced-function CYP2D6 alleles appear to have 
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significantly lower circulating endoxifen concentrations than those with wild-type CYP2D6. 
It has also been shown that use of CYP2D6 inhibitors such as SSRIs and SNRIs has a 
negative impact on the efficacy of tamoxifen. Together, these studies support the notion that 
low CYP2D6 activity, caused by genetic polymorphisms or drug interactions, leads to low 
levels of the active tamoxifen metabolite ( Jin Y, 2005; Lim HS, 2007; Hoskins JM, 2009). The 
effect of CYP2D6 activity on tamoxifen pharmacokinetics also translates into an effect on 
clinical outcome. Despite conflicting data in some instance, the majority of retrospective 
studies suggest that the presence of nonfunctional or reduced-function alleles of CYP2D6 is 
associated with worse outcome of patients receiving tamoxifen. A recent large retrospective 
analysis of 1325 patients with early-stage breast cancer treated with adjuvant tamoxifen 
suggests that compared with extensive metabolizer, those with decreased CYP2D6 activity 
(heterozygous extensive/intermedidate and poor metabolizers) have significantly increased 
risk of recurrence as well as worse event-free survival and disease-free survival (Schroth W, 
2009). In addition, CYP2D6 genotype has also been shown to influence the efficacy of 
tamoxifen as a chemopreventive agent, whereby tamoxifen-treated women with poor 
metabolizer phenotype was associated with a significantly higher incidence of breast cancer 
compared with controls (Higgins MJ, 2010). Findings from these studies support a role for 
the CYP2D6 genotype in the activation of tamoxifen and likelihood of therapeutic benefit 
from testing for CYP2D6 genoptype. 
6. Consequences of epigenetic factors on PG and PK 
Genetic polymorphisms exhibited by many of the Phase-I and Phase-II drug-metabolizing 
enzymes as well as both passive and active drug-transporters, can alter drug distribution, 
drug metabolism and drug-drug interactions and are of great clinical relevance. However, a 
number of other factors may also contribute to the variation in polymorphism activity, 
including; (1) environmental factors, (2) age, sex and ethnicity of the patient, (3) 
physiological status, and (4) disease state. Therefore, in addition to genetic variations, 
changes in CYP450 enzyme functions and ABC and SLC transporter activities are 
responsible for the occurrence of adverse effects or lack of therapeutic efficacy of drugs in 
many cases. 
6.1 Drug-drug interactions regulate drug disposition 
Many coadministered drugs can increase or decrease the activity of various CYP isozymes, 
by either inducing the biosynthesis of an isozyme (enzyme induction) or by directly 
inhibiting the activity of the CYP (enzyme inhibition). If one drug inhibits the CYP-mediated 
metabolism of another drug, the second drug may accumulate within the body to toxic 
levels. Hence, these drug interactions may necessitate either dosage adjustments or choosing 
drugs that do not interact with the CYP system (Anglicheau D, 2003). Such drug interactions 
are especially important to take into account when using drugs of vital importance to the 
patient. Drugs with important side-effects and drugs with small therapeutic windows may 
be subject to an altered plasma concentration due to altered drug metabolism. A classical 
example includes anti-epileptic drugs (Li XQ, 2004; Li Y, 2008). CYP450 enzyme induction 
can occur following repeated administration of antibiotics such as Rifampin (Zhang HX, 
2009). Numerous immunosuppressive drugs such as cyclosporine-A and FK-506, used in 
organ transplantation, show potent drug interactions and are important in 
pharmacogenetics (Thervet E, et al, 2008). Certain drugs can cause CYP enzyme inhibition 
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by either binding to the cytochrome component or act to competitively inhibit drug 
metabolism. The histamine (H2) receptor antagonist, Cimetidine (Tagamet) and the 
antifungal agent, Ketoconazole (Nizoral) are known to be potent inhibitors of multiple 
CYPs. Several antibiotics can cause catalytic inactivation of CYPs as well. The Macrolide 
antibiotics (e.g. erythromycin), which are themselves metabolized by CYPs are known to 
complex with the cytochrome heme-iron, producing a complex that is catalytically inactive. 
In addition, Chloramphenicols which are also substrates of CYPs have been shown to 
inactivate these enzymes by their direct inactivation. It is expected that poor metabolizers 
would have higher concentrations of a drug that is inactivated by that enzyme pathway and 
therefore require a lower dose to avoid adverse reactions, whereas ultrarapid metabolizers 
would require a higher dose to achieve therapeutically effective drug concentrations. The 
opposite pattern of reactions is expected for a drug that undergoes metabolic activation. 
Both tobacco use and drugs of abuse, as well as dietary factors can impact CYP450 enzymes 
and ABC transporters, expression and function. One of the most documented relationships 
between disease and transporter expression is the association between the overexpression of 
ABC transporters and the concomitant increased efflux of chemotherapeutic drugs such as 
vinca-alkaloids, epipodophyllotoxins, and anthracyclines.  
6.2 Social and dietary factors regulate drug disposition 
Increasing evidence supports the assertion that one mechanism behind clinically significant 
herb-drug and food-drug interactions is interference at the level of ABC transporters and CYP 
enzymes (Zhang W, 2005; Marchetti et al., 2011). Naturally occurring compounds may also 
induce or inhibit CYP activity. For instance, grapefruit, orange, and pimelo juices inhibit 
CYP3A4 and P-gp function, which impacts metabolism and increases drug bioavailability, and, 
thus, the strong possibility of overdosing. Approximately 10% of all admissions in general 
hospitals are the result of inappropriate administration of drugs or combinations of drugs that 
can cause severe to lethal drug-drug or herb-drug interactions. Grapefruit Juice, regularly used 
as a digestive and dieuretic agent, is also known to be a potent inhibitor of CYPs (Bailey DG, 
1998). The drugs most susceptible to pharmacokinetic interactions with citrus juices are those 
with a narrow therapeutic index and a reported affect by P-gp or CYP enzymes; thus, 
physicians and patients should be cognizant of these clinically significant food-drug interactions 
when prescribing or following drug treatment (Marchetti et al., 2011). The principle compounds 
in these Citrus fruits, furanocoumarins and flavonoids, cause interactions with over 50% of the 
most commonly prescribed drugs in major drug classes such as antiallergics, antibiotics, 
anxiolytics, calcium channel blockers and HIV protease inhibitors (Cuciureanu M, 2010; Kakar 
SM, 2004; Pillai et al., 2009). In contrast, although regular consumption of these citrus juices may 
decrease the therapeutically efficacious dose required, co-administration with drugs such as 
astemizole, terfenadine, or verapamil may severely increase drug plasma levels and result in 
toxicity or fatality (Bailey et al., 1998; Pillai et al., 2009).  
Several other dietary components and supplements influence drug bioavailability. For 
example, Watercress is also a known inhibitor of CYP2E1, which may result in altered drug 
metabolism for individuals on certain medications (e.g., chlorzoxazone) (van Erp NP, 2005). St. 
John's Wort (SJW), a common herbal remedy and antidepressant, can induce CYP3A4, and 
also inhibit multiple CYP enzymes such as CYP1A1, CYP1B1 and CYP2D6 (Schwarz UI, 2007; 
Lei HP, 2010; Lau WC, 2011). Clinical studies demonstrated that coadministration of SJW 
significantly reduced plasma concentrations of drugs including oral contraceptives, warfarin, 
www.intechopen.com
 
Readings in Advanced Pharmacokinetics – Theory, Methods and Applications 
 
84
verapamil and fexofenadine which was associated with both failures of therapies and under 
treatment (Marchetti et al., 2011). Coadministration of SJW and the HIV protease inhibitor, 
indinavir, or the cardiac glycoside, digoxin increased intestinal P-gp expression and produced 
significantly lower plasma area under the concentration-time curves. Chronic administration 
of SJW and cyclosporine-A significantly reduced plasma levels of cyclosporine-A, and 
increased acute organ rejection in transplanted patients. Curcumin, curcuminoids and 
catechins from green tea reduce P-gp expression in vitro and reports indicate that piperine, 
ginsenosides, capsaicin, resveratrol and silymarin inhibit in vitro P-gp activity.  
Socially used factors such as tobacco and alcohol activate receptors that modulate P-gp and 
CYP expression. A genetic polymorphism in the regulatory sequences of human CYP2E1 has 
been associated with increased liver toxicity following ethanol consumption, especially in 
obese individuals (McCarver DG, 1998). Tobacco smoking also induces CYP1A2 and changes 
the bioavailability of numerous CYP1A2 substrates such as clozapine and olanzapine (Bartsch 
H, 2000). Significantly greater non-small cell lung cancer tumors were P-gp positive in smokers 
compared to non-smokers (Volm et al., 1991). Although it remains unclear if P-gp expression 
levels definitively play a defensive role towards tobacco-derived agents, there is a correlation 
between current smoking and resistance to the anthracycline drug doxorubicin. Therefore, 
significant amount of current literature verifies that drug bioavailability can be modulated by 
components in foods and herbs that regulate drug-metabolizing enzymes and drug-
transporters. Hence, dietary components and herbal supplements has important clinical 
implications, especially in those individuals containing specific augmenting or suppressing 
polymorphisms in their CYP450 enzymes and/or ABC-transporters. 
6.3 Drug disposition: Effects age, sex and ethnicity 
Aging is characterized, in part, by alterations in all stages of pharmacokinetic processes 
(absorption, distribution, metabolism, and excretion), several of which can affect the 
safety/efficacy profile of a variety of drugs (McLeod HL, 1992; Aronoff GR, 1999; Bjorkman 
S. 2006; Corsonello A, 2010). The elderly population is more sensitive to bleeding 
complications arising from warfarin administration which may be attributed to variations in 
CYP2C9 function. In addition, elderly patients are especially susceptible to adverse drug 
reactions due to comorbidity, use of multiple pharmaceutics, and age-related changes in PK 
(Burk O, 2002; Anglicheau D, 2003). Specific CYPs are inhibited by numerous drugs 
commonly prescribed to elderly patients, a fact that may help explain significant 
pharmacological interactions. For instance, the distribution of drugs acting on the CNS can 
be significantly affected by the changes of BBB permeability which occurs with aging. 
Several drugs are effluxed via the activity of cerebrovascular P-gp at the BBB; therefore, age-
related regression in P-gp function could increase drug levels in the CNS (Corsonello et al., 
2010). The CYP450-mediated hepatic drug clearance in neonates, infants and children were 
found to differ significantly from adults and was a predictor of drug response (Bjorkman S. 
2006). The hepatic clearance of drugs in older patients can be reduced more than 40%, some 
of which may be attributed to alteration in CYP enzyme activity. Although some studies 
suggest that CYP-mediated activity and enzyme affinity for their substrates are not altered 
during the aging process, clinically relevant changes in drug-metabolizing enzyme 
expression have been observed. For instance, a clear age-related decline (20%) in the 
metabolism of CYP2D6 substrates has been demonstrated (Corsonello et al. 2010; Dorne et 
al., 2002; O’Connell et al., 2006). Selective serotonin reuptake inhibitors (SSRIs) can inhibit 
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CYP2D6 activity and therefore reduce the efficiency of drugs that need to be activated by 
CYP2D6 when coadministered, such as tamoxifen and codeine. The antiplatelet drug 
clopidogrel is prescribed to prevent stroke and heart attack and it requires CYP2C19 for 
activation. Omeprazole, a drug used to treat gastroesophageal reflux disease, is both a 
substrate and an inhibitor of CYP2C19. As a result, individuals with reduced CYP2C19-
mediated activity will suffer from impaired clopidogrel bioactivation and enhanced 
accumulation of omeprazole (Furuta et al., 1998; Li et al., 2004; Roden et al., 2009).  
The predominant enzymes involved in phase I hepatic drug metabolism are CYPs, several of 
which show clear sex-related differences and impact drug clearance (Soldin OP, 2009). 
Individuals exhibit great variation in biotransformation and although most ‘sex-dependent’ 
differences are eliminated with correction for height, as well as weight, composition, and 
surface area of the body, sex-dependent differences in biotransformation of a few drugs such 
as nicotine, aspirin, heparin, flurazepam, and chlordiazepoxide have been demonstrated. For 
instance, the activity of enzymes CYP1A and CYP2E1 is higher in men, while a higher activity 
of CYP2D6 and CYP3A4 enzymes have been observed in women (O’Connell MB, 2006). A 
series of physiological changes that are known to affect drug plasma concentrations occur 
during gestation and pregnancy, one of which causes significant changes in CYP enzyme 
activity. To date, the PK data amassed pertaining to menopause-related intestinal and hepatic 
CYP3A4 activity found no significant differences in biotransformation and drug clearance in 
pre- and postmenopausal women. Sex-related and pregnancy-related changes in drug 
metabolism and elimination may guide changes in dosage regimen or therapeutic monitoring 
to reduce possible toxicity and increase drug efficacy (Soldin and Mattison, 2009).  
Race related changes in the CYP enzyme and ABC transporter activation and regulation 
may alter drug accumulation and contribute to the increasing occurrence of adverse drug 
reactions in elderly patients. Pharmacodynamic differences between races can be associated 
with changes in drug transporters, and both differences in baseline performance and 
sensitivity to treatment is attributed to drug efflux from tissues. For instance, some drugs 
may penetrate the CNS more readily with advancing age thereby increasing their 
bioavailability. The variation in frequency of SNPs for MDR1 in different racial/ethnic 
populations has been previously documented. Allelic frequency can differ among these 
groups (Kim RB, 2001; McLeod H. 2002; Hesselink DA, 2004). The incidence of C/T and 
C/C genotypes at position 3435 has been found to be much higher in African than in 
Caucasian or Asian populations (Wang D, 2005; Wang J, 2006). One crucial factor regulating 
drug levels is African Americans is P-gp function since decreases in P-gp expression has 
been linked to increased drug serum concentrations and extended drug residence time 
within the brain (Tirona RG, 2001). While only 26% of Caucasians and 34% of Japanese were 
homozygous for the C allele, 83% of Ghanaians and 61% of African Americans were 
homozygous for the C allele (Xie XG, 2001. Certain common allelic variants of CYP3A4 were 
found to be highly prevalent in different minority populations (Lamba JK, 2002a & 2002b 
Koch I, 2002). Population distribution and effects on drug metabolism of a genetic variant in 
the promoter region of CYP3A4 were also previously documented (Ball SE, 1999; Schaeffeler 
E, 2001). In fact, the functional decline in P-gp may play a role in the increased sensitivity to 
selected benzodiazepines such as flurazepam reported in patients with specific P-gp SNPs. 
Therefore, individualized prescriptions for patients should incorporate knowledge from 
basic pharmacology, race or ethnicity, clinical practice and pharmacosurveillance (Sim SC, 
2005; Corsonello et al., 2010). Therefore, age, sex and race related changes in the CYP 
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enzyme and ABC transporter activation and regulation may alter drug accumulation and 
contribute to the increasing occurrence of adverse drug reactions.  
6.4 Patient health status dictate drug disposition 
The most noteworthy condition which alter drug bioavailability in patients is chronic renal 
failure (CRF) which has been shown to significantly reduce renal clearance of drugs which are 
predominantly metabolized by the liver and intestine (Bjorkman S, 2006). Patients with CRF 
exhibit decreased volume of distribution for a variety of drugs due to reduced renal and skeletal 
muscle mass and decreased tissue binding. In both preclinical and clinical studies, drug 
transporters such as P-gp and CYPs are affected. In fact, CRF causes a 40 to 85 % 
downregulation of hepatic and intestinal CYPs with high levels of hormones, cytokines, and 
uremic toxins also reducing CYP activity. The alteration in these enzymes and proteins affects 
drug bioavailability and increases the risk for adverse drug reactions (Dreisbach and Lertora 
2008; Dreisbach 2009). In transplant patients on cyclosporine-A or tacrolimus, studies have 
shown changes in both CYP3A4 and P-glycoprotein activity in healthy controls and patients 
(Lemahieu WP, 2004).  In addition to the condition or disease alone regulating enzyme activity 
and transporter expression, consideration should be applied during treatment for patients on 
multiple medications (van der Deen M, 2005). P-gp can regulate drug uptake in the CNS and is 
expressed constitutively in endothelial cells that form the BBB. The expression, however, can be 
activated or inhibited by other compounds or modified under pathological conditions. For 
instance, antipsychotics, antiepileptics, or antidepressants that are P-gp substrates can interact at 
the P-gp level and may be responsible for some documented cases of drug resistance. An 
induction of P-gp expression decreases psychotropic drug uptake in the central nervous system, 
which ultimately reduces drug efficacy (Wikinski, 2005). While the health of a patients during 
treatment may be primarily shaped by their disease and drug disposition, social factors will also 
influence treatment outcome and should be taken into account during therapeutic decisions. 
7. Drug efflux-drug metabolism alliance 
There is considerable overlap in the substrate selectivity and tissue localization of specific 
groups of CYP450 enzymes and ABC transporters (Benet LZ, 2001 & 2004).  Common 
substrates, inhibitors and inducers for CYP3A and P-gp clearly implicate that both common 
regulatory mechanisms and cross-talk between this CYP iso-enzyme and drug-efflux pump 
can ultimately regulate drug disposition. Interestingly, in CYP3A4-transfected Caco-2 cells the 
expression of several efflux transporters, e.g. P-gp, MRP1, and MRP2 were upregulated, 
especially after stimulation of cells with either the protein kinase-A (PKA) inducer sodium 
butyrate or the protein kinase-C (PKC) inducer phorbol ester 12-O-tetradecanoylphorbol-13-
acetate (PMA) (Cummins, CL, 2001 & 2002). In an in vivo intestinal perfusion model, these 
investigators had also shown modulation of intestinal CYP3A metabolism by P-gp (Cummins, 
CL, 2003). This has led to the hypothesis that both drug-transporter and drug-metabolizing 
enzymes act as a coordinated barrier against xenobiotic agents. Several animal studies using 
mdr1a (−/−) knockout mice have demonstrated P-gp’s importance in limiting drug absorption 
and decreasing bioavailability. Human clinical studies investigating the importance of 
intestinal CYP3A and P-gp through inhibition or induction of these proteins have provided 
further evidence of this interaction. Recent in vitro studies using CYP3A4-expressing Caco-2 
cells reveal that the role of P-gp in the intestine not only limits parent drug absorption, but also 
increases the access of drug to metabolism by CYP3A through repeated cycles of absorption 
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and efflux. These early findings suggested a biochemical link or coregulation of the drug-efflux 
and drug-metabolism functions in cells (Benet LZ, 2001; Cummins CL, 2002). A number of 
recent studies further corroborate this dynamic interplay between different ABC-transporters 
and different Cyp450 enzymes (Lam JL, 2006; Lee NH, 2010). These studies, carried out in 
cellular systems, isolated organ, whole animal and human studies, have elucidated the 
importance of these interacting processes. The importance of this phenomenon with respect to 
the intestine and the liver, characterizing inhibition and induction of apical and basolateral 
transporters and how drug metabolism can change independent of any change in the 
metabolic enzymes, has been effectively shown.  
8. Conclusions 
As alluded to in the previous section, drug-drug interactions, environmental and 
physiological factors significantly contribute to inter-individual variability in drug PK. 
However, these differences are not sufficient to explain the significant heterogeneity 
associated with patient responses to therapeutic agents and their narrow therapeutic 
indices. Continued investigation and adaptation of PG with respect to understanding PK 
should provide improved benefit to therapeutic efficacy versus side-effect profiles of many 
drugs currently available. Studies are being translated to clinical practice via molecular 
diagnostics (genotyping) and identifying relevant inherited variations that may better 
predict patient response to chemotherapy. Among these, nucleotide repeats, insertions, 
deletions, and SNPs, which can alter the amino acid sequence of the encoded proteins, RNA 
splicing and gene transcription particularly in drug-metabolizing enzymes and drug 
transporters have been actively explored with regard to functional changes in phenotype 
(altered expression levels and/or activity of the encoded proteins) and their contribution to 
variable drug response. Recent studies also indicate that information on combination of 
polymorphisms that are inherited together (haplotype analysis) can often result in better 
correlation with phenotypes than with individual polymorphisms. The potential is 
enormous for PG to yield a powerful set of molecular diagnostic methods that will become 
routine tools with which clinicians will select medications and drug doses for individual 
patients. Gene-expression profiling and proteomic studies are evolving strategies for 
identifying genes that may influence drug response. Thus, patient oriented PG will provide 
a very unique approach towards increasing the therapeutic efficacies of numerous anti-
cancer, anti-viral as well as anti-diabetic drugs. Furthermore, an effective re-evaluation of 
new drug design toward the generation of specific therapies focused on drugs that are not 
critically affected by the Cyp450 enzymes and the drug-transporter biology may eventually 
lead to personalized and individualized medicine. However, there are a number of issues 
which must be considered before developing strategies that target these inherited 
determinants of drug effects. One formidable challenge would be the fact that these 
inherited components are often polygenic and a complex interplay between genetic and 
epigenetic factors may ultimately dictate drug disposition. Therefore, the limitations of the 
current PG approaches will be the lack of complete knowledge and understanding of the 
complex mechanisms of drug distribution and drug-drug interactions. Another very 
important hurdle in correctly delineating the pharmacogenetic traits that regulate 
individualistic differences is the need for well characterized in vivo models. Studies in 
transgenic and knockout animals are proving highly efficacious in this respect, but only 
accounts for monogenic traits. Patient populations, with race, gender and ethnicity 
specified, who have been uniformly treated and systematically evaluated for drug action 
and toxicities, will be highly instrumental in making it possible to quantify the role of 
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different CYP450 enzymes and ABC-transporters, objectively. The marked population 
heterogeneity has deterred a clear understanding of the effects of specific genotypes and 
their importance in determining efficacy. The effects of a medication for one population or 
disease may not as effective for another population; therefore, PG relations must be 
validated for each therapeutic indication and in different racial and ethnic groups, which 
will indeed be a daunting task. However, since genotyping methods are improving rapidly, 
it will be possible to test for thousands of polymorphisms which determine patient 
responses. In a clinical setting, it should be easy to collect patient samples and carry out a 
panel of genotypes and test for those which are important determinants of drug disposition. 
With the advent of new computer programming and new softwares to delineate pathways 
and interactions, it will be possible to simplify the complexities of the alliances between 
drug metabolizers and drug transporters. We believe that in the near future, genotyping 
results will be of great clinical value only if they are interpreted according to the patient’s 
diagnosis. An effective and safe treatment option can then be recommended by the 
physician. 
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